Jan Boren

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 325 publications

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: June 25, 2026

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal: Journal of internal medicine

Published: June 11, 2026

A pcyt-1 Allelic Series Reveals In Vivo Consequences of Reduced Phosphatidylcholine Synthesis in C. elegans.

A pcyt-1 Allelic Series Reveals In Vivo Consequences of Reduced Phosphatidylcholine Synthesis in C. elegans.

Journal: bioRxiv : the preprint server for biology

Published: May 04, 2026

A pcyt-1 allelic series reveals in vivo consequences of reduced phosphatidylcholine synthesis in C. elegans.

A pcyt-1 allelic series reveals in vivo consequences of reduced phosphatidylcholine synthesis in C. elegans.

Journal: G3 (Bethesda, Md.)

Published: April 22, 2026

Lipoprotein(a) - the hereditary risk factor for cardiovascular disease

Lipoprotein(a) - the hereditary risk factor for cardiovascular disease

Journal: Lakartidningen

Published: March 20, 2026

Tunable Aromatic Sulfoxides and Sulfones as Cysteine-Targeting Warheads: Exploring the Structure-Reactivity Relationship.

Tunable Aromatic Sulfoxides and Sulfones as Cysteine-Targeting Warheads: Exploring the Structure-Reactivity Relationship.

Journal: Journal of medicinal chemistry

Published: March 09, 2026

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH.

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH.

Journal: Frontiers in pharmacology

Published: March 04, 2026

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

Journal: European heart journal

Published: February 28, 2026

Forward genetics identifies cuticle and regulatory genes underlying cellular boundary integrity in C. elegans.

Forward genetics identifies cuticle and regulatory genes underlying cellular boundary integrity in C. elegans.

Journal: G3 (Bethesda, Md.)

Published: February 03, 2026

Galectin-3 associates with NF-κB activation and mitochondrial redox-related protein signatures in catecholamine-induced stress cardiomyopathy.

Galectin-3 associates with NF-κB activation and mitochondrial redox-related protein signatures in catecholamine-induced stress cardiomyopathy.

Journal: Molecular medicine (Cambridge, Mass.)

Published: January 30, 2026

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Journal: Current atherosclerosis reports

Published: January 07, 2026

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Journal: Pharmacology & therapeutics

Published: December 15, 2025

Showing 1-12 of 325

Last Updated: 09/26/2026